All populations considered, it appears that the greatest impact on IA prediction of US examination can be found in three at-risk populations: those with a positive ACPA test in the context of non-specific MSK symptom, those with CSA, and those with palindromic rheumatism. The gene discussed is PRTN3; the disease is chromosome-type aberration frequency.